OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work

OpenAI Group PBC has acquired Orchestra Bio Inc., a startup specializing in AI agents for pharmaceutical development. The company's technology and staff will be integrated into Rosalind, OpenAI's dedicated life sciences unit. This strategic move aims to utilize AI agents to manage drug development grunt work and keep programs on track. By folding Orchestra Bio into Rosalind, OpenAI bets that artificial intelligence can significantly reduce the decade-plus timeline typically required to bring new medicines to patients.